Skip to content

Prospective Cohort Study of Psittacosis Pneumonia in the Real World: Evaluation of Risk Factors for Severe Disease and Comparative Effectiveness of Antibiotics

Prospective Cohort Study of Psittacosis Pneumonia in the Real World: Evaluation of Risk Factors for Severe Disease and Comparative Effectiveness of Antibiotics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114496
Enrollment
Unknown
Registered
2025-12-12
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psittacosis pneumonia

Interventions

Observational group:None

Sponsors

The Second Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Meet the diagnostic criteria for community-acquired pneumonia, with Chlamydia psittaci positivity confirmed by mNGS or PCR; 3. Chest imaging confirms pneumonia; 4. Hospitalization duration >=24 hours. 5. Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding; 2.Combined with mixed infections of other definite pathogens (bacteria, fungi, tuberculosis); 3.Discharged or deceased within 24 hours of admission; 4.Missing more than 30% of key clinical data. 5. The investigator determines that inclusion is not appropriate.

Design outcomes

Primary

MeasureTime frame
Demographic characteristics (including age, sex, occupation, medical history, etc.);Clinical manifestations (including presence or absence of fever, chills, joint pain, muscle pain, sore throat, cough, sputum production, hemoptysis, palpitations, and chest tightness, etc.);Laboratory tests (including complete blood count, C-reactive protein, procalcitonin, transaminases, serum creatinine, albumin, D-dimer, and oxygenation index, etc.);Imaging findings (including lesion location, number of involved lung lobes, CT characteristics, presence or absence of mediastinal lymphadenopathy and pleural effusion, etc.);Treatment interventions (including use of mechanical ventilation, ventilator settings, types and duration of antibiotic use);Patient prognosis and outcomes;

Countries

China

Contacts

Public ContactFeng Ganzhu

The Second Affiliated Hospital of Nanjing Medical University

zhu1635253@163.com+86 189 5176 2691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026